Table 2.
Description of patients, tumor, and management of simple genomic sarcoma
| Age at diagnosis | Stage and histological subtype | Tumor location | Treatment | TRKi | Follow-up |
|---|---|---|---|---|---|
| 44 years | Localized LNT | Shoulder | Surgery | — | 4 months CR |
| 13.4 years | Localized LNT | Hand | Surgery three times for local relapse | Entrectinib at the third local relapse | 3.4 years CR |
| 31 years | Localized cutaneous NTRK-rearranged spindle neoplasm | Shoulder | R1 surgery | — | 5 months CR |
| 65.4 years | Metastatic PNST | Lung and pleura metastases | R1 surgery + RT | Entrectinib at metastatic relapse | 8 months PFS |
| 10 months | Locally advanced IMT | Peritoneum | R1 surgery | Neoadjuvant larotrectinib | 3.7 years CR |
| 5.4 years | Localized IMT | Lung | R0 surgery | — | 1.1 years CR |
| 45.8 years | Localized IMT | Lung | R0 surgery | — | 4.8 years CR |
| 74 years | Metastatic GIST | Liver and peritoneal metastases | Adjuvant imatinib + first-line sunitinib | Cabozantinib as the second line | 15 months PFS |
CR, complete response; GIST, Gastro intestinal stromal tumor; IMT, inflammatory myofibroblastic tumor; LNT, lipofibromatosis neural tumor; PFS, progression-free survival; PNST, peripheral nerve sheath tumor; RT, radiotherapy; UK, unknown.